Shukra Pharmaceuticals hit a 2% upper circuit after signing an exclusive PAN India distribution agreement with Wockhardt. Under this deal, Shukra will manage distribution and payment collection for Wockhardt’s advanced anti-infective products across ESIC, defence, and AFMSD hospitals, boosting its reach and revenue visibility.